The objective of this study was to examine the impact of introducing rosuvastatin calcium on direct and indirect costs among patients at high risk for coronary heart disease.
An economic simulation model was developed to project the number of cardiovascular events and associated direct and indirect costs under varying treatment scenarios.
In an average-sized commercial health plan with 210,000 covered lives and 9,336 high-risk patients, an uptake of rosuvastatin by 11% of high-risk patients would result in eight fewer cardiovascular events, a net savings of $0.85 million in direct medical costs and a net savings of $36,404 in productivity loss over a period of 5 years. The overall reduction in total costs is equivalent to $1735 per rosuvastatin-treated patient.
At current statin prices, the use of rosuvastatin could lead to fewer cardiovascular events and lower direct and indirect costs.
From Thomson Medstat (Dr Song, Mr Huse, Dr Ozminkowski), Ann Arbor, Michigan; and AstraZeneca Pharmaceuticals LP (Dr Williams, Dr Borok, Dr McDonough), Wilmington, Delaware.
CME Available for this Article at ACOEM.org
Daniel M. Huse is employed by Thomson Medstat. He has no commercial interest related to this article.
Address correspondence to: Daniel M. Huse, MA, Thomson Medstat, 125 Cambridgepark Drive, Cambridge, MA 02140; E-mail: Dan.Huse@Thomson.com.